Expansion Into Latin America And US Injectables Will Strengthen Future Prospects

Shared on01 May 25
Fair value Decreased 0.67%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 0.68%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 2.83%

Shared on26 Mar 25
Fair value Decreased 0.93%

AnalystConsensusTarget has increased revenue growth from 14.2% to 16.5% and decreased future PE multiple from 34.0x to 30.5x.